Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma

Tislelizumab in combination with chemotherapy is being developed for the first-line treatment of
locally advanced, unresectable or metastatic gastric cancer (GC) or gastroesophageal junction
(GEJ) adenocarcinoma. GC is a cancer that starts in the stomach. GEJ adenocarcinoma is cancer
that starts at the gastro-oesophageal junction, where the food pipe (oesophagus) joins the
stomach. Risk factors of GC and GEJ adenocarcinoma include smoking, alcohol consumption,
obesity, older age, gastro-oesophageal reflux disease and long-term helicobacter pylori infection.
Symptoms can include difficulty and pain when swallowing, nausea or vomiting, heartburn,
indigestion, loss of appetite, fatigue, unexplained weight loss, or a lump in the upper abdomen.